ArticleARYA atherosclerosis2025
Protective effects of crocin against contrast induced acute kidney injury following angiography: A randomized controlled clinical trial.
Article in ARYA atherosclerosis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe use of contrast media in angiography has risen alongside the increasing incidence of cardiovascular diseases. Contrast agents cause acute kidney injury due to increased oxidative stress. Antioxidants such as crocin may help prevent contrast-induced acute kidney injury (CI-AKI).
methodsA randomized controlled clinical trial involved 60 patients over 18 years old undergoing Percutaneous Coronary Intervention (PCI). Standard hydration therapy was administered to the patients in both groups. The intervention group received 30 mg crocin three consecutive times. Oxidative stress levels and antioxidant system activity were measured, including malondialdehyde (MDA), reactive oxygen species (ROS), glutathione peroxidase (GPx), catalase (CAT), and superoxide dismutase (SOD). The prevalence of CI-AKI was also examined by measuring serum creatinine (SCr), blood urea nitrogen (BUN), and the estimated glomerular filtration rate (eGFR).
resultsThe analysis found no statistically significant differences between the groups for the GPx, CAT, MDA, ROS, SOD, SCr, BUN, and eGFR indices (P > 0.05). The study found a significant decrease in the average SCr and BUN in the intervention group post-PCI (P < 0.05). There were two incidences of CIN in the control group and none in the intervention group; however, the two groups did not differ significantly (P = 0.492). Conclusion: Although oral administration of 30 mg of crocin did not lead to significant changes in oxidant biomarkers, the capacity of the antioxidant defense system tended to increase. Moreover, SCr, BUN, and the incidence of CI-AKI were lower in the intervention group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.